|
End-of-day quote
Taiwan S.E.
2026-10-08
|
5-day change | 1st Jan Change | ||
| 56.90 TWD | +1.43% |
|
+1.61% | +6.26% |
| Market Cap | 10.28B 321M 287M 267M 243M 459M 31.11B 461M 3.21B 1.26B 15.86B 1.21B 1.18B 50.9B | P/E 2024 |
12.6x | P/E 2025 | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 8.84B 277M 247M 230M 209M 395M 26.76B 396M 2.76B 1.08B 13.64B 1.04B 1.02B 43.78B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.29x |
| Free-Float |
44.21% | Yield 2024 |
4.52% | Yield 2025 | 3.4% |
| 1 day | +1.43% | ||
| 1 week | +1.61% | ||
| Current month | +1.07% | ||
| 1 month | +1.61% | ||
| 3 months | -2.05% | ||
| 6 months | -0.81% | ||
| Current year | +6.26% |
| 1 week | 55.7 |  | 57.5 |
| 1 month | 55.6 | | 57.5 |
| Current year | 53.55 | | 60.55 |
| 1 year | 48.64 | | 60.55 |
| 3 years | 46.55 | | 72.18 |
| 5 years | 33.95 | | 72.36 |
| 10 years | 24.86 | | 72.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zi Ting Fan
CEO | Chief Executive Officer | - | 2006-05-29 |
Reynold Hsu
DFI | Director of Finance/CFO | - | 2019-07-15 |
Shu Hua Chen
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Zi Ting Fan
CHM | Chairman | - | - |
Yuan Te Li
BRD | Director/Board Member | - | 2012-06-05 |
Tsui Wen Yeh
BRD | Director/Board Member | - | 2002-05-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +1.61% | +14.84% | +2.44% | 318M | |
| -0.03% | +3.22% | +44.00% | +93.28% | 1,051B | |
| +0.46% | +3.91% | +37.67% | +68.11% | 630B | |
| +1.08% | +5.18% | +21.38% | +88.49% | 489B | |
| -0.28% | +4.22% | +69.70% | +40.39% | 359B | |
| +0.61% | +3.18% | +24.10% | +42.46% | 344B | |
| +0.72% | +2.99% | +14.79% | +34.71% | 272B | |
| +0.23% | +2.23% | -5.49% | +8.15% | 246B | |
| +0.16% | +3.18% | +42.20% | +45.87% | 224B | |
| -0.63% | +3.99% | +27.23% | +95.93% | 187B | |
| Average | +0.31% | +2.73% | +29.04% | +51.98% | 380.4B | |
| Weighted average by Cap. | +0.23% | +2.93% | +34.44% | +66.52% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 6.79B 212M 190M 176M 161M 303M 20.56B 304M 2.12B 832M 10.48B 798M 780M 33.63B | 7.02B 220M 196M 183M 166M 313M 21.26B 315M 2.2B 861M 10.84B 825M 807M 34.79B |
| Net income | 881M 27.55M 24.6M 22.89M 20.82M 39.3M 2.67B 39.47M 275M 108M 1.36B 103M 101M 4.36B | 928M 29.02M 25.92M 24.11M 21.93M 41.41M 2.81B 41.59M 290M 114M 1.43B 109M 107M 4.6B |
| Net Debt | -1.24B -38.9M -34.74M -32.32M -29.4M -55.51M -3.77B -55.75M -389M -152M -1.92B -146M -143M -6.16B | -1.44B -44.93M -40.13M -37.33M -33.95M -64.11M -4.35B -64.39M -449M -176M -2.22B -169M -165M -7.11B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-08 | NT$56.90 | +1.43% | 701,718 |
| 26-10-07 | NT$56.10 | +0.36% | 106,810 |
| 26-10-06 | NT$55.90 | +0.18% | 114,654 |
| 26-10-05 | NT$55.80 | -0.36% | 305,488 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1720 Stock
Select your edition
All financial news and data tailored to specific country editions
